NEW YORK, May 23, 2026, 17:10 EDT
- Johnson & Johnson finished Friday at $234.34, rising 1.13%. The stock was up about 3.4% on the week.
- U.S. stock markets stay shut Monday for Memorial Day. The next cash session is set for Tuesday.
- J&J investors are watching new China drug approval news, AI surgery updates, and a planned May 27 appearance as the short week starts.
Johnson & Johnson shares gained 1.13% on Friday, closing at $234.34, and ended the week up about 3.4%. That put the Dow name ahead of the S&P 500’s weekly move going into the U.S. Memorial Day holiday.
Big healthcare stocks are drawing buyers as investors look past tech and the market rally picks up steam. The S&P 500 logged an eighth consecutive weekly gain. The Dow Jones Industrial Average finished Friday at a new record high.
Healthcare stocks also found some buyers. Nine out of 11 big S&P 500 sectors ended higher Friday, Reuters said, with healthcare near the top. That gave J&J a boost ahead of Monday’s market holiday.
The most recent news from the company wasn’t an earnings print, but it kept focus on the pipeline. J&J’s nipocalimab got approved in China for people 12 and up with generalized myasthenia gravis, a muscle-weakening immune disorder, Reuters reported Thursday.
China’s market already has other approved drugs for the disorder, with Reuters listing Hansoh Pharmaceutical Group, Zai Lab, and Argenx as competitors. Launch timing and pricing could be key for J&J. The company didn’t give Reuters any immediate comment on those points.
J&J spent the week talking up its medical tech business. The company said that Abu Dhabi’s health regulator plans to standardize operating rooms using Polyphonic, J&J’s open digital surgery platform, working with partners like Amazon Web Services and NVIDIA. “No single company, hospital, or developer can do this alone,” said Hani Abouhalka, company group chair for surgery at J&J MedTech. JNJ.com
The gains still depend on the April earnings reset. J&J upped its 2026 forecast last month, targeting reported sales of $100.8 billion at the midpoint and adjusted earnings per share of $11.55. Adjusted earnings per share excludes certain items the company says are outside normal operations.
Joaquin Duato, CEO, said the quarter was a “strong start to 2026.” He pointed to ICOTYDE’s approval for plaque psoriasis and VARIPULSE Pro’s European nod as possible ways to drive long-term returns. J&J management is set to speak next on Wednesday at Bernstein’s Strategic Decisions Conference, 11:00 a.m. ET. Johnson & Johnson Investor Relations
Looking to the week ahead, things could get tougher. U.S. markets shut Monday. Then investors turn to fresh inflation and growth numbers, with the Personal Consumption Expenditures price index—watched by the Fed—on the agenda for May 28.
But there are plenty of risks. J&J warns that gains from its Abu Dhabi tie-up could take longer than forecast, or not show up at all. The company lists competition, regulatory hurdles, commercial outcomes, safety concerns, and efforts to keep healthcare costs down as key uncertainties. For the stock, a slow China rollout, new pricing headwinds or an upside surprise on inflation could make last week’s move look overdone.
Market tone is supportive for now. “Earnings season looked really good,” James St. Aubin, chief investment officer at Ocean Park Asset Management, told Reuters. He said recent economic data has been “pretty solid” except for a few outliers. J&J has to prove its drug pipeline and medical-tech investments can keep up with a stock price that’s already jumped this month. Reuters
